Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database
Table 6
Cox model for the effect of bone metastasis combined with another metastatic organ site on PFS stratified by study.
Parameter
Levels
Hazard ratio for first-line treatment (95% CI)
value (first-line)
Hazard ratio for second-line or higher treatment (95% CI)
value (second line or higher)
Bone and liver metastases
Bone present—liver absent
1.00
0.185
1.00
0.149
Bone present—liver present
1.68 (0.78, 3.63)
2.16 (0.76, 6.15)
Bone and lymph node metastases
Bone present—lymph nodes absent
1.00
0.040
1.00
0.742
Bone present—lymph nodes present
1.99 (1.03, 3.85)
0.84 (0.30, 2.34)
Bone and lung metastases
Bone present—lung absent
1.00
0.030
1.00
0.205
Bone present—lung present
2.80 (1.10, 7.09)
2.45 (0.61, 9.84)
Bone and soft-tissue metastases
Bone present—soft-tissue absent
1.00
0.299
1.00
0.175
Bone present—soft-tissue present
0.68 (0.33, 1.40)
1.94 (0.75, 5.04)
Bone and other metastases
Bone present—other absent
1.00
0.112
1.00
0.082
Bone present—other present
0.56 (0.27, 1.15)
0.41 (0.15, 1.12)
Hazard ratios were adjusted for demographic characteristics, histological entity, tumour grade, site of primary tumour, and time between histological diagnosis and registration/randomisation.
